EN DE
Watch LAMEDITECH Co., Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LAMEDITECH Co., Ltd. (462510) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of LAMEDITECH Co., Ltd. stock KRW 1,525, price KRW 1,820, that is 16.2% below the price, quality 29 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

LC LAMEDITECH Co., Ltd. logo Thin data Nov 10, 2026

LAMEDITECH Co., Ltd.

462510 · KQ
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Expensive Growth (revenue 3y +51.8 %/yr in KRW)
Moderate debt
Revenue last quarter 31% below a year ago.
Fair value 1,525 KRW · Overvalued
Quality 29/100
Loss-making · -175.4% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 12/100
Thin data
Estimate
Watch LAMEDITECH Co., Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

24,550 KRW 1,742 KRW Fair Value 1,525 KRW Jun 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

29‑month range 1,742 KRW – 24,550 KRW · fair‑value band 1,144 KRW – 1,906 KRW · the 1,820 KRW price screens above the 1,525 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow LAMEDITECH Co. in your weekly email

Every Wednesday you see whether LAMEDITECH Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lameditech Co., Ltd. develops, manufactures, and sells laser blood samplers and medical devices in South Korea.

Show moreShow less

It offers laser lancing devices under the HandyRay-Lite and HandyRay names; HandyRay-Pro, a professional laser blood collection device for hospitals and medical institutions; CAREVEAM, a device designed for the treatment of various skin diseases with its 308nm excimer light system; and Ray-Vet, a UVB light irradiation therapy system designed to treat inflammatory skin diseases and various auto-immune diseases in pets and animals.

The company was founded in 2012 and is headquartered in Seoul, South Korea.

Stock analysis

LAMEDITECH Co., Ltd. (462510) currently trades at 1,820 KRW, while our estimate is 1,525 KRW, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 1,144 KRW (bear) to 1,906 KRW (bull), the price of 1,820 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

LAMEDITECH Co., Ltd. reported revenue of 7.2B KRW in FY2025 versus 2.1B KRW in FY2022, a compound +51.8%/yr. Reported net income was −11.4B KRW in FY2025.

Key figures

Market cap 22.2B KRW (≈ $16.7M) Micro · P/S ratio 4.00 · EPS (TTM) −1,108 KRW · Return on equity −102% · Return on assets (EBIT) −41.0% (4-year average) · Operating margin −149% · Revenue (TTM) 5.6B KRW · Revenue growth (YoY) −31.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 75% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −16%, 462510 screens richer than that median.

Fair Value

Bear 1,144 KRW Fair Value 1,525 KRW Bull 1,906 KRW
Price 1,820 KRW · Downside -16.2%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 29/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 42
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 70
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−162.7% (2022) → −164.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

462510 screens overvalued: fair value 16% below the price. Compare with Abbott Laboratories, →

Compare LAMEDITECH Co., Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 29 · Bottom 25%
Fair Value upside −16.2% · Below median
Profitability
Return on assets −45.1% · Bottom 25%
Net margin (12 months) −175.4% · Bottom 25%
Operating margin (12 months) −149.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −31.3% · Bottom 25%
Balance sheet
Debt / equity 0.52× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 2.64× · Pricier than median
P/S (12 months) 4.00× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 17
FUTURE (revenue growth)0 · sector 44
PAST (return on equity)0 · sector 0
HEALTH (low debt)74 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 462510
DexCom, Inc DXCM $79.92 $89.18 +12% vs 462510
Stryker Corporation SYK $324.29 $358.30 +10% vs 462510
STERIS plc STE $257.12 $279.53 +9% vs 462510
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 462510
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 462510
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 462510
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 462510
Medtronic plc MDT $101.59 $65.61 −35% vs 462510
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 462510

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LAMEDITECH Co., Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "LAMEDITECH Co., Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/462510

Frequently asked questions

Is LAMEDITECH Co., Ltd. (462510) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 1,525 KRW versus a price of 1,820 KRW, about 16% lower (overvalued).
What is the fair value of 462510?
Our estimate for LAMEDITECH Co., Ltd. is 1,525 KRW (as of Nov 10, 2026), built from audited fundamentals. The current price: 1,820 KRW.
What is the quality score of 462510?
LAMEDITECH Co., Ltd. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LAMEDITECH Co., Ltd. (462510)?
Our calculated price target is the estimate of 1,525 KRW (as of Nov 10, 2026). Cautious scenario 1,144 KRW, optimistic scenario 1,906 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the LAMEDITECH Co., Ltd. stock forecast for 2026?
Our estimate puts fair value at 1,525 KRW, about 16% lower versus a price of 1,820 KRW (overvalued). Cautious scenario 1,144 KRW, optimistic scenario 1,906 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of LAMEDITECH Co., Ltd. (462510)?
LAMEDITECH Co., Ltd. reported trailing-twelve-month revenue of about 5.6B KRW (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of LAMEDITECH Co., Ltd. (462510)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LAMEDITECH Co., Ltd. it is 1,525 KRW per share (as of Nov 10, 2026), against a price of 1,820 KRW.
Is LAMEDITECH Co., Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 462510 trades above its calculated fair value: price 1,820 KRW, fair value 1,525 KRW, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 462510?
No. The price is what the market pays today (1,820 KRW); the fair value is what the company's own numbers justify (1,525 KRW). For LAMEDITECH Co., Ltd. the two are 295.24 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is LAMEDITECH Co., Ltd. worth?
The market values LAMEDITECH Co., Ltd. at about 22.2B KRW (market capitalisation, as of Nov 10, 2026). Per share that is 1,820 KRW; our models calculate a fair value of 1,525 KRW per share.
What do the bullish and bearish scenarios say about 462510?
Our models span a range for LAMEDITECH Co., Ltd.: cautious scenario 1,144 KRW, base 1,525 KRW, optimistic 1,906 KRW per share (as of Nov 10, 2026, price 1,820 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LAMEDITECH Co., Ltd. (462510)?
Balance-sheet figures for LAMEDITECH Co., Ltd. (as of Nov 10, 2026): return on equity −102.2%, debt of 0.52 per unit of equity. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is 462510 from its 52-week high?
LAMEDITECH Co., Ltd. trades at 1,820 KRW, about 75% below its 52-week high of 7,300 KRW and 4% above the low of 1,742 KRW (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 1,525 KRW is for.
Which stocks are comparable to LAMEDITECH Co., Ltd.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LAMEDITECH Co., Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 1,820 KRW, calculated fair value 1,525 KRW (−16%), Quality Score 29/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. LAMEDITECH Co., Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LAMEDITECH Co., Ltd. (462510)?
The closing price on Nov 10, 2026 was 1,820 KRW. Our estimate is 1,525 KRW, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LAMEDITECH Co., Ltd. right now?
Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of LAMEDITECH Co., Ltd.

How large is the market capitalisation of LAMEDITECH Co., Ltd. (462510)?
The market capitalisation of LAMEDITECH Co., Ltd. is 22.2B KRW (≈ $16.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LAMEDITECH Co., Ltd. (462510)?
The price-to-sales ratio of LAMEDITECH Co., Ltd. is 4.00 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LAMEDITECH Co., Ltd. (462510)?
Earnings per share at LAMEDITECH Co., Ltd. are −1,108 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of LAMEDITECH Co., Ltd. (462510)?
The return on equity (ROE) of LAMEDITECH Co., Ltd. is −102% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LAMEDITECH Co., Ltd. (462510)?
On an EBIT basis the return on assets of LAMEDITECH Co., Ltd. is −41.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LAMEDITECH Co., Ltd. (462510)?
The operating margin of LAMEDITECH Co., Ltd. is −149% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LAMEDITECH Co., Ltd. (462510)?
Revenue at LAMEDITECH Co., Ltd. is growing −31.3% versus a year earlier (3y avg +51.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LAMEDITECH Co., Ltd. (462510) generate?
The free cash flow of LAMEDITECH Co., Ltd. is −15.3B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does LAMEDITECH Co., Ltd. (462510) carry?
The net debt of LAMEDITECH Co., Ltd. is 1.9B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch LAMEDITECH Co., Ltd. in the live analysis

One click puts LAMEDITECH Co., Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.